Antibody recognizing folate receptors alpha and beta
US-2015343088-A1 · Dec 3, 2015 · US
Compositions comprising chimeric OSPA molecules and methods of use thereof
US9023367B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9023367-B2 |
| Application number | US-201313939759-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 11, 2013 |
| Priority date | Jul 27, 2012 |
| Publication date | May 5, 2015 |
| Grant date | May 5, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising a combination of polypeptides, wherein the combination comprises (i) a polypeptide comprising the amino acid sequence with at least 90 percent sequence identity to the amino acid sequence set forth in SEQ ID NO:2, (ii) a polypeptide comprising the amino acid sequence with at least 90 percent sequence identity to the amino acid sequence set forth in SEQ ID NO:4, and (iii) a polypeptide comprising the amino acid sequence with at least 9…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K38/164Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9023367B2 cover?
- The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combinati…
- Who is the assignee on this patent?
- Baxter Int, Baxter Healthcare Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K38/164. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).